0000000000247091

AUTHOR

Hiromasa Inoue

showing 3 related works from this author

GINA 2019: a fundamental change in asthma management

2019

GINA no longer recommends treating adults/adolescents with asthma with short-acting bronchodilators alone. Instead, they should receive symptom-driven (in mild asthma) or a daily corticosteroid-containing inhaler, to reduce risk of severe exacerbations.http://bit.ly/310LLzE

AdultPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAdolescentMild asthmaGlobal HealthAsthma managementAdministration InhalationHumansMedicineAnti-Asthmatic AgentsDisease management (health)Monitoring PhysiologicRandomized Controlled Trials as TopicAsthmaInhalationbusiness.industryInhalerDisease Managementmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesBudesonide/formoterolPractice Guidelines as TopicFundamental changebusinessmedicine.drugEuropean Respiratory Journal
researchProduct

Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes

2021

Funder: Global Initiative for Asthma

ExacerbationRespiratory SystemINHALED CORTICOSTEROIDSCritical Care and Intensive Care MedicineAsthma managementSINGLE-INHALERDOUBLE-BLINDRisk Factorsimmune system diseasesAdrenal Cortex HormonesRELIEVER THERAPYFormoterol FumarateMedicine and Health SciencesImmunology and AllergyAnti-Asthmatic AgentsChild11 Medical and Health SciencesLung functionMILD PERSISTENT ASTHMAExecutive summaryBiologic therapiesCombined Modality TherapyLUNG-FUNCTIONChild PreschoolPractice Guidelines as TopicPerspectiveDisease ProgressionDrug Therapy Combinationmedicine.drugPulmonary and Respiratory MedicineAdultmedicine.medical_specialtyBUDESONIDE/FORMOTEROL MAINTENANCEAdolescentMild asthmaMEDLINEInhaled corticosteroidsCONTROLLED-TRIALSkills trainingGINA Strategy 2021: Executive SummaryBUDESONIDE-FORMOTEROLAdministration InhalationmedicineHumansasthma preventionIntensive care medicineSEVERE EXACERBATIONSAsthmaasthma diagnosisbusiness.industryPatient AcuityInfantasthmamedicine.diseaseAsthmarespiratory tract diseasesSelf Carewf_140Formoterolwf_100businessasthma management
researchProduct

Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications

2017

Asthma is a complex respiratory disorder characterized by marked heterogeneity in individual patient disease triggers and response to therapy. Several asthma phenotypes have now been identified, each defined by a unique interaction between genetic and environmental factors, including inflammatory, clinical and trigger-related phenotypes. Endotypes further describe the functional or pathophysiologic mechanisms underlying the patient's disease. type 2-driven asthma is an emerging nomenclature for a common subtype of asthma and is characterized by the release of signature cytokines IL-4, IL-5 and IL-13 from cells of both the innate and adaptive immune systems. A number of well-recognized bioma…

0301 basic medicineImmunologyDiseasePeriostin03 medical and health sciencesTh2 Cells0302 clinical medicineImmune systemT-Lymphocyte SubsetsmedicineAnimalsHumansImmunology and AllergyAsthmaInflammationbusiness.industrymedicine.diseasePhenotypeAsthmaPathophysiologyrespiratory tract diseases030104 developmental biology030228 respiratory systemExhaled nitric oxideImmunologyCytokinesSputumInflammation Mediatorsmedicine.symptombusinessBiomarkersSignal TransductionClinical & Experimental Allergy
researchProduct